nivatrotamab
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 17, 2021 (NCT04750239)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD3E agonist
- Disialoganglioside GD2BINDING AGENT
Disialoganglioside GD2
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650409 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04750239 | Phase 1/Phase 2 (Phase 2) | Aug 17, 2021 | Y-Mabs, Inc |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Y-Mabs, Inc | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1